Why can't NWBO provide just a general update regarding how they are managing this trial without revealing any other information. That would seem reasonable to shareholders buying this stock, right? What to the private investors get to know about the ongoing trials? Seems reasonable we should get something versus nothing. Especially for our patience here.
My understanding of AA is that it allows for provisional approval until data can be provided that supports full approval and that the overall approval process is shortened because of this. I agree with you that the wording applies to at least provisional approval so that patients can have earlier access to treatments that demonstrate a strong liklihood of being beneficial. Maybe I am just splitting hairs about what "approval" means. The latest guidance seems to strengthen the provisional position to the point that only future data indicating problems would affect approval status. Best wishes.
Market Data 
Markets 
AI
